| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction
NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide
Class-leading weight loss driven by best-in-class pharmacology and brain penetration of NMRA-215
Neumora plans to initiate Phase 1 clinical study in the first quarter of 2026
WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced positive preclinical data for NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor from three diet-induced obesity (DIO) mouse studies. NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction and 26% in combination with semaglutide.
Posted In: NMRA
